LONDON — Treatment with the antidepressant fluoxetine does not decrease progression in multiple sclerosis (MS), results of a new randomized controlled trial show. First results released from the FLUOX ...
Last month, a retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS) ...
A minority of patients with multiple sclerosis (MS) have primary progressive disease, and it has few treatment options. The challenges of developing treatments for primary progressive multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results